Physician profile
Asma Arif
NPI 1891732483
$4,265.87
in general payments reported to CMS, 2019-2025
35 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $374 · 2021: $1,072 · 2022: $1,023 · 2023: $678 · 2024: $466 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.76 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $810.90 | 2019-2023 | Xifaxan |
| Abbvie INC. | $776.55 | 2021-2024 | Rinvoq, Skyrizi, Qulipta |
| Janssen Biotech, INC. | $752.05 | 2019-2025 | Stelara, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $236.46 | 2019-2021 | |
| Sk Life Science, INC. | $165.85 | 2022-2023 | |
| Pfizer INC. | $146.38 | 2019-2021 | |
| Gilead Sciences, INC. | $140.01 | 2019-2025 | |
| Csl Behring | $121.47 | 2021-2023 | Hizentra |
| Merck Sharp & Dohme LLC | $117.76 | 2020-2024 | |
| Argenx US, INC. | $104.55 | 2022-2023 | Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $89.78 | 2019-2025 | Entyvio |
| Celgene Corporation | $64.97 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $64.75 | 2021-2023 | Amyvid |
| Regeneron Healthcare Solutions, INC. | $62.25 | 2023-2024 | Dupixent |
| Emd Serono, INC. | $52.10 | 2022-2023 | Mavenclad |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45.01 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $44.57 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $40.70 | 2022-2023 | Linzess |
| Livanova USA, INC. | $37.76 | 2022 | |
| Novo Nordisk INC | $34.07 | 2025 | |
| Ferring Pharmaceuticals INC. | $31.59 | 2023 | Clenpiq |
| Exact Sciences Corporation | $28.86 | 2023 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $28.16 | 2023 | Ingrezza, Ongentys |
| Ardelyx, INC. | $27.99 | 2024 | Ibsrela |
| Qol Medical, LLC | $25.79 | 2021 | |
| Ucb, INC. | $25.69 | 2022 | |
| Aimmune Therapeutics, INC. | $25.30 | 2024 | |
| Intercept Pharmaceuticals, INC. | $25.00 | 2024 | |
| Genzyme Corporation | $23.78 | 2024 | |
| Supernus Pharmaceuticals, INC. | $22.03 | 2021 | |
| Amgen INC. | $21.12 | 2021 | |
| Grifols USA, LLC | $19.68 | 2021 | |
| Biogen, INC. | $18.62 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.32 | 2021 | |
| Redhill Biopharma INC. | $16.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Arif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.